ENVALITH
第一工業製薬株式会社 logo

DKS Co.Ltd.

4461Prime MarketChemicals

第一工業製薬株式会社 logo
DKS Co.Ltd.4461

Governance

The Board of Directors consists of 7 members, including 3 outside directors (outside ratio approximately 43%), and the company has adopted the Audit & Supervisory Board structure. It has established a voluntary Nomination Committee, Compensation Committee, and Advisory Board, with independent outside directors serving as committee chairs to ensure fairness and transparency in decision-making.

Outside Director Ratio

42.9%

Nomination Committee

Established

Compensation Committee

Established

Risk Management

A Risk Management Control Committee, chaired by the responsible executive officer, meets four times a year to identify, evaluate, and respond to risks based on the PDCA cycle. A multi-layered structure has been established in which legal risks are handled by the Compliance Control Committee and the Security Export Control Committee, environmental/safety/quality risks by the RC Promotion Conference, financial risks by the internal audit department, and information risks by the information systems department.

Shareholder Returns

Basic policy is to maintain a long-term, stable dividend, paid twice a year. For FY2026 (ending March 2026), the annual dividend per share is ¥150 (interim ¥60, year-end ¥90), with a payout ratio of 24.7%. The forecast for FY2027 (ending March 2027) is an annual dividend of ¥150 (¥75 interim and ¥75 year-end). Disposal of treasury shares (public offering) was carried out.

Dividend Policy

The basic policy is to maintain a long-term and stable dividend, balanced against the internal reserves needed for future business development. Dividends are paid twice a year, as an interim dividend and a year-end dividend. For FY2026 (ending March 2026), taking into account performance in the first year of the medium-term management plan “SMART 2030,” the year-end dividend was increased by ¥35 from the previous year-end to ¥90 (annual dividend of ¥150, payout ratio of 24.7%). For FY2027 (ending March 2027), an annual dividend of ¥150 (¥75 interim, ¥75 year-end) is planned, factoring in growth investments such as human capital investment, R&D, and capital expenditures, as well as uncertainties in the external environment such as geopolitical risk. The policy is to use internal reserves for strategic investments aimed at strengthening international competitiveness and creating new growth opportunities.

Dividend

Paying

Share Buyback

None

Shareholder Benefits

None

ESG

The company supports the TCFD and has set a target of reducing GHG emissions (Scope 1+2) by 30% by FY2030 compared to FY2013 levels (a 16.0% reduction was achieved in FY2025), with a goal of carbon neutrality by 2050. In terms of human capital, it has set KPIs such as labor productivity of ¥9.7 million per employee (FY2030 target) and a 15% ratio of female managers, and has been certified as a Certified Health & Productivity Management Outstanding Organization (White 500) for nine consecutive years, promoting sustainability management centered on climate change, human rights, and human resource development.

Last updated: June 19, 2026